Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.
News|Articles|January 15, 2025
CDC: 2013-2023 youth risk physical activity behavior report
Author(s)Joshua Fitch, Senior Editor
Across all years in the report, the CDC rated each physical activity trend with a color of red, indicating that trends are going in the "wrong direction."
Advertisement
Advertisement
The Youth Risk Behavior Survey (YRBS) Data Summary & Trends Report for Dietary, Physical Activity, and Sleep Behaviors: 2013–2023 provided insights into the physical activity behaviors of US high school students. The report, developed by the CDC, highlights trends over the past decade, revealing concerning patterns in physical activity engagement among adolescents.
Related to this article
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.
At AAP 2026, Justin Wheeler, MD, discussed bowel cleanouts, maintenance therapy, and behavioral strategies for managing constipation in children.
Justin Wheeler, MD, explains how pediatricians can identify constipation across age groups and distinguish overflow incontinence from diarrhea.
Mark R. Corkins, MD, CNSC, FASPEN, AGAF, FAAP, reviews where pediatric probiotic evidence is strongest, why product quality varies, and which children should avoid them.
At AAP 2026, Carmen Tong, DO, discussed evaluating pediatric urinary symptoms and why behavioral strategies often come before medication.
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
In a Hirschsprung disease mouse model, diet shifted gut microbes and inflammation, with a 3-fold survival difference between standard diets.
Advertisement
Advertisement